Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit

P Joret-Descout1, S Dauger2,3,4, M Bellaiche5

  • 1Département de Pharmacie, Hôpital Robert-Debré, AP-HP, 48 boulevard Sérurier, 75395, Paris Cedex 19, France.

Insights

Implementing stress ulcer prophylaxis (SUP) guidelines significantly reduced proton pump inhibitor (PPI) use and dosage in a pediatric intensive care unit (PICU). This change occurred without an increase in gastrointestinal bleeding, demonstrating guideline effectiveness.

Area of Science:

  • Pediatric Intensive Care
  • Pharmacology
  • Clinical Practice Guidelines

Background:

  • Stress ulcer prophylaxis (SUP) is a standard intensive care unit (ICU) practice to prevent gastrointestinal bleeding.
  • Proton pump inhibitors (PPIs) are increasingly prescribed for SUP, raising concerns about overuse and off-label use.
  • Evidence-based guidelines aim to optimize medication prescribing patterns in critical care settings.

Purpose of the Study:

  • To evaluate the impact of disseminated pediatric intensive care unit (PICU) guidelines on proton pump inhibitor (PPI) prescribing patterns.
  • To assess changes in PPI prevalence, dosage, and indications for stress ulcer prophylaxis (SUP) post-guideline implementation.

Main Methods:

  • A prospective observational study was conducted in a pediatric ICU.
  • Two 6-week observation periods were compared: before and after the introduction of PPI prescribing guidelines.
  • Data collected included PPI prevalence, dosage, and indication for stress ulcer prophylaxis.

Main Results:

  • The proportion of patients receiving PPIs for SUP significantly decreased from 51% to 30% after guideline implementation (p < 0.001).
  • Mean daily PPI dosage also significantly decreased from 1.5 mg/kg to 1.1 mg/kg (p < 0.002).
  • No upper gastrointestinal bleeding events were observed in either study period.

Conclusions:

  • Off-label PPI prescribing for stress ulcer prophylaxis was prevalent in the pediatric ICU.
  • The implementation of prescribing guidelines led to a significant reduction in PPI use and dosage.
  • Clinical practice guidelines are effective in modifying PPI prescribing patterns in pediatric critical care.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
628
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304